Sort   by:  
 Page size 
UnknownPhase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.
Not available
S-EPMC6141244 | biostudies-literature
UnknownArginine deprivation/citrulline augmentation with ADI-PEG20 as novel therapy for complications in type 2 diabetes.
Not available
S-EPMC11414555 | biostudies-literature
UnknownTargeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin.
Not available
S-EPMC4467438 | biostudies-literature
UnknownDifferential expression of argininosuccinate synthetase in serous and non-serous ovarian carcinomas.
Not available
S-EPMC4858122 | biostudies-literature
UnknownRole of 3'-Deoxy-3'-[<sup>18</sup>F] Fluorothymidine Positron Emission Tomography-Computed Tomography as a Predictive Biomarker in Argininosuccinate Synthetase 1-Deficient Thoracic Cancers Treated With Pegargiminase.
Not available
S-EPMC9445378 | biostudies-literature
UnknownPhase 1 trial of ADI-PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors.
Not available
S-EPMC8729058 | biostudies-literature
UnknownExpansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1-Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms.
Not available
S-EPMC8474273 | biostudies-literature
UnknownEpigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma.
Not available
S-EPMC3563985 | biostudies-literature
UnknownA role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
Not available
S-EPMC10227144 | biostudies-literature
UnknownPhase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies.
Not available
S-EPMC8076217 | biostudies-literature
Sort   by:  
 Page size